Alderley Health Sciences Ltd

• Your four goals for the next six to twelve months, winning more customers, improving quality and consistency, getting better data and reporting, and automating manual work, are all reasonable in isolation. The problem is that they require very different investments and have very different timescales. Winning more customers is a channel and pipeline problem. Improving consistency points to process and content. Better reporting is a systems and integration problem. Automating manual work overlaps with all three. Without ranking these by commercial impact and by what is realistic given your current capacity, you risk spreading your marketing manager and designer across too many projects simultaneously, and making incremental progress on all of them rather than meaningful progress on any.

• The procurement cycle shapes everything for you in a way that most marketing plans ignore. Your market does not work like a retail or direct-to-consumer business, where you can run a campaign at any time and expect enquiries to follow. NHS and local-authority procurement runs on tender windows, framework agreements and budget sign-off cycles. Your marketing and sales activity needs to be sequenced around those windows, building visibility and relationship depth in the periods before tenders open, not during them. Right now there is no documented strategy for doing that.

• The key-person dependency risk you identified is a commercial problem as much as an operational one. The two most senior sales representatives hold the majority of clinical relationships personally, with no structured handover process in place. If either person leaves, those relationships do not automatically transfer. Making those relationships visible and at least partially transferable, through documented contact history, shared account notes and a consistent communication rhythm that the business owns rather than the individual, is one of the highest-priority structural fixes you have.

• Your current marketing is relationship-led by design, and that is not wrong for this sector. But it creates a ceiling. If the only way to win a new clinical account is a personal visit from a senior rep, growth is constrained by how many visits two people can physically make. The practical opportunity is to use digital channels to extend and support those relationships rather than replace them, so that by the time a rep visits, the prospect already understands what you do and why it matters.

• Compliance and regulation are a genuine constraint on what you can say and where you can say it, and they should be treated as a design parameter, not an afterthought. The MHRA rules on medical device advertising and promotional claims are specific and enforceable, and they limit the kind of content marketing that works freely in other sectors. That does not mean no content marketing is possible, but it does mean the content strategy needs to be built around what you are permitted to say, which in practice means educational, evidence-based material aimed at commissioners and procurement leads rather than promotional copy aimed at end users.

• The gap between your importance score for this element (80 out of 100) and your current performance score (43 out of 100) tells you something direct: the business recognises that strategy and challenge-setting matter, but has not yet translated that recognition into a working plan. The Digital Transformation Audit is the step that closes that gap, because it converts the priority list from a general ambition into a ranked set of projects, each with a measurable target and a realistic effort estimate, so you can commit properly to two or three things rather than attempting everything at once.

• The field sales team of twelve relies on individual quoting and proposal habits. Without a shared template or a structured brief-to-quote process, two reps quoting the same GP practice are probably producing two different documents at two different speeds, and neither version necessarily reflects the current pricing or product positioning. A single approved proposal template, version-controlled and held centrally, removes that inconsistency without slowing anyone down.

• Recruiting sales reps with genuine clinical credibility is your stated pressure point, and it is a real one because the talent pool is small and interview-to-offer cycles in regulated healthcare tend to be slow. The onboarding problem that follows is less visible but equally costly: if your product knowledge, clinical evidence summaries and compliance expectations live in people's heads rather than in a proper onboarding pack, every new starter costs the business weeks of senior-staff time. A structured onboarding document, even a well-organised shared folder with the right files in the right order, compresses that significantly.

• Reporting and spreadsheets appearing on your most time-consuming list suggests that performance data is currently assembled manually, probably by pulling exports from different systems and combining them. That is a solvable problem. Armadello, Anicca's analytics and reporting product, would bring your channel activity, spend, traffic and commercial outcomes into one place so the marketing team and leadership are not spending hours each week building the same view from scratch.

• Your marketing team of three is small relative to the range of outputs expected: dressings, diagnostics, skincare, practice bundles and CPD webinars are five distinct product and service lines, each with a different buyer and a different message. Without a clear brief template and a documented sign-off process, the risk is that the marketing manager and designer spend as much time chasing approvals as they do producing work. A one-page brief template and a named sign-off owner per product category would materially reduce that friction.

• The EU expansion question, specifically whether to pursue CE marking for limited European sales, has a structural implication your current team should be aware of: with six people in quality and regulatory, adding a CE marking programme alongside existing MHRA obligations is a real workload commitment, not just a registration exercise. That is not a marketing decision, but it shapes what the marketing team is asked to prepare, so it is worth being deliberate about sequencing before it creates pressure on people who are already fully deployed.

• Your existing Google Ads activity is a live channel worth examining in the context of how enquiries are handled once they arrive. If the telesales and account management team of eight is fielding a high volume of recurring questions that could be answered by better website content or a structured FAQ, that is time being spent twice: once to generate the enquiry, and once to answer it manually. Identifying the ten most common enquiry types and addressing them in your content is a practical step that neither requires new headcount nor competes with the sales team's relationship work.

The problem is that you are not systematically growing what they spend with you, and you are not turning that loyalty into a structured source of new business.

Who you are selling to

• Your primary buyer is well defined: the practice manager owns the budget and the lead nurse shapes the product choice. That dual-influence dynamic matters because most of your acquisition effort, reps, telephone sales, catalogue, is almost certainly aimed at one person. If your materials and follow-up do not speak to both, you are leaving the clinical influencer to form their own view without any support from you.

• The 60/20 split between GP surgeries and community NHS framework business is a sensible base, but framework agreements can create a false sense of security. The account exists, the orders arrive, and no one is actively developing it. You should know, for each framework account, what share of that practice's or provider's total consumables spend you actually hold. If you do not know that number, you cannot tell whether the account is healthy or slowly being spread across other suppliers.

• Private podiatry and aesthetics clinics at 15% of revenue are worth watching. You described them as higher-margin and faster to decide. That profile means a different sales approach is probably warranted, and the economics of winning and keeping those customers may look quite different from a GP surgery account. It is worth understanding whether the six-year, £45,000 figure holds for that segment or whether lifetime value is shorter and the margin difference makes up for it.

Winning customers

• You are acquiring business through field sales, telephone outreach, tenders, referrals, and catalogue. That is a mature, relationship-led model that suits regulated B2B healthcare well. The honest question is not whether those channels work, it is whether each one is tracked well enough for you to know which is actually delivering the most profitable accounts, not just the most orders. Your existing Google Ads activity is one channel to interrogate here: are the enquiries it generates converting into accounts with similar lifetime value to those won through reps, or are they smaller and shorter?

• Clinical references and case studies exist but live inside sales relationships, not anywhere a buyer or influencer can find them independently. In a sector where product decisions carry clinical weight, that informal arrangement means your strongest evidence is invisible at the moment a practice manager is comparing suppliers online or a lead nurse is asking a colleague for a recommendation.

Keeping and growing customers

• The cross-sell gap you identified is the most immediate commercial opportunity in this element. A GP surgery buying wound dressings that has never been shown the diagnostic consumables range is an account that is underserving you and possibly being approached by a specialist supplier who does make that connection. Reps doing this ad hoc means it happens for some accounts and not others, depending on who visits and when. A simple account-profiling approach, mapping which product categories each account buys against what they could reasonably buy, would let you run structured conversations rather than hoping the topic comes up.

• Your NPS measurement is one-off and unsystematic. That is not a criticism of the intention, but a one-off survey gives you a point-in-time reading rather than an early warning signal. You do not need a complex programme to improve on this: a short, timed check-in at months three, twelve and thirty-six of an account relationship, tied to account management calls you are already making, would give you trend data and flag dissatisfied accounts before they drift or merge without telling you. Armadello would give you a single view of those account health signals alongside purchasing behaviour, so your account managers are not relying on memory or separate spreadsheets to spot which relationships need attention.

• Referrals are generating new business, but with no systematic process behind them. In a market where clinical trust matters and cold outreach has limits, a structured referral process would cost very little and protect a channel that is genuinely valuable. That does not have to mean a formal incentive scheme; in a regulated context it might simply mean making it easy for a satisfied practice manager to pass on a name, and following up with the named contact in a way that references the relationship without putting the referrer in an awkward position.

• Your email and newsletter programme is a retention tool you already run. The question is whether it is doing anything beyond keeping your name in front of accounts, or whether it is being used to show existing customers what else you offer, signal clinical authority, or prompt buying conversations at the right point in the purchasing cycle. A marketing manager and designer in-house means you have the resource to make this more deliberate without adding headcount.

It is a workflow problem that a few structural decisions can largely fix.

Customer communications

• The overlap between field reps and telesales contacting the same practice without knowing it is the most immediately damaging pattern you described. A practice that receives two separate conversations about the same product, with no acknowledgment that the other conversation happened, reads that as disorganisation. The fix is not a culture change programme; it is visibility. Whoever owns your CRM needs to enforce a simple rule: every outbound contact, including phone calls, is logged against the practice record before the rep moves on. If that is not happening consistently now, the question is whether it is a process gap or a CRM adoption gap, and those have different answers.

• Your CPD webinars and clinical evidence bulletin are the strongest communications assets you have. A tissue-viability nurse fronting quarterly wound-care content is not something most medical device suppliers can put in front of a practice, and the fact that both formats perform well confirms that the clinical audience values them. The bottleneck is compliance sign-off, which slows release and will eventually affect the frequency or ambition of both formats if nothing changes. The practical move is to build a pre-approved content framework: a set of structures, approved claim categories and language patterns that the quality and regulatory lead signs off once, which your marketing manager and designer then work within for each individual piece. This does not remove compliance oversight; it moves the bulk of the review upstream so individual bulletins and webinar scripts require a lighter check against an already-approved template rather than a full review from scratch every time.

• Your product update communications are being described by practices as reading like regulatory documents. That is a signal that the compliance review process is shaping the writing rather than checking it. The drafting and the reviewing are two separate jobs, and the tone of the final piece should reflect the writer, not the reviewer. Separating those two stages, and briefing the quality lead to review for accuracy and compliance rather than to edit for style, would preserve the clinical credibility of your content without the impenetrability that is currently frustrating your audience.

• Your email segmentation is at a useful level, with segments and interest tags already applied. The next step is making sure those tags actually govern what each segment receives, rather than sitting as metadata that does not change the send. If practices tagged as wound-care specialists are receiving the same bulletin as general practice contacts with different procurement interests, the segmentation is doing nothing for you. A straightforward audit of whether your tag logic maps to your actual send logic is worth an hour of someone's time before you invest further in list growth.

• LinkedIn is listed as a live channel. For a regulated B2B supplier talking to NHS and independent practice buyers, LinkedIn is one of the few platforms where clinical and procurement audiences coexist. The opportunity is not primarily paid; it is using your existing clinical content, the webinar recordings and the evidence bulletin, to build a visible presence for the business and for your tissue-viability nurse as a recognisable voice in the sector. That kind of presence builds trust with people who are not yet on your email list.

• The in-app or portal channel you listed is worth examining separately. If practices are logging in to place orders or access clinical resources, the portal is the one place where you have their full attention with no inbox competition. Whether that is currently being used as a communications surface, for product updates, CPD reminders or service messages, is worth checking, because it is often under-used relative to email.

Internal and team communications

• The field rep and telesales overlap problem is partly an internal communications failure before it becomes a customer-facing one. The two teams are clearly not sharing a live view of which practices they are each talking to, or on what subject. This does not require a new platform; it requires an agreed protocol, enforced in your existing CRM, so that before any outbound contact a rep checks the practice record and notes their own activity afterwards. The harder question is whether the two teams are currently measured and managed as if they operate in separate channels, because if their targets and reporting do not require coordination, they will not coordinate.

• The compliance review process is a communications bottleneck that affects internal speed as much as external output. The quality and regulatory lead is a finite resource, and routing every marketing piece through a full review is consuming time that could be spent on genuinely novel or high-risk content. Building the pre-approved framework described above would reduce the volume of work landing on the quality lead without reducing their authority over what goes out. That is a conversation between marketing and quality, and it is worth having formally rather than letting the current friction persist.

• You mentioned that a named contact who understands medical device marketing constraints is what works best in an external partner relationship, with quarterly reviews sufficient given your campaign volume. That preference reflects a mature internal communications culture: you are not looking for weekly check-ins or a high volume of creative iterations. What it does mean is that the handoff briefing at the start of any external engagement needs to be thorough, because the external partner will be working with relatively infrequent touchpoints and needs to have absorbed the regulatory context, the sign-off process and the tone requirements fully before the first piece of work is produced.

• The AI signal in your marketing operation is worth naming plainly here. Your marketing manager is using ChatGPT for drafting, with every output reviewed before it is used, which is a sensible working practice given the MHRA advertising rules on medical device claims. The board has identified the need for a proper policy, particularly before any AI tool touches customer data. Structuring that policy, covering which tools are sanctioned, what data they may and may not access, and how staff use is governed, is the work of Anicca's separate AI Adoption Roadmap rather than this report, but the gap is live and worth closing before informal use drifts into areas the business has not yet considered.

There are no formal brand guidelines, no documented voice or messaging framework, and by your own description the audit exists only in people's heads. In a regulated B2B environment where buyers are comparing you against established competitors, that inconsistency costs you credibility you have already earned through the quality of the work itself.

What you produce and where it falls short

• Your content mix is well-matched to how regulated healthcare buyers actually make decisions: clinical evidence, structured CPD, detailed product information. The gap is not the formats you choose but the way they are produced and connected to each other. A tender document and a clinical evidence sheet may be written by different people at different moments, with no shared language tying them back to the same organisation.

• No formal brand guidelines means every piece is effectively a first draft from a brand perspective. The logo and colour scheme exist, but voice, tone, and how you frame claims about your products are not written down anywhere. That means new copy, whether drafted by your marketing manager, your designer, or ChatGPT, has no single reference point to check against before it goes out.

• The twice-yearly printed catalogue is a significant production effort and cost. Without a content calendar that integrates the catalogue cycle with your digital content, you are likely producing digital and print in separate bursts rather than using each to support the other. The evidence sheets that go out with every product launch are exactly the kind of asset that should be feeding your organic search content and your HubSpot email sequences, but without a structured pipeline, they probably live in a folder and stop working the moment the launch is over.

• Tender documents are constant, by your description, yet they sit entirely outside the content system. If the language and evidence in your tenders is not being drawn from a central, approved library of claims, you are rewriting the same points repeatedly and introducing inconsistency across submissions. This is one of the highest-effort, highest-stakes content tasks you do, and it has no infrastructure behind it at the moment.

• Your existing tools, Adobe Creative Cloud for designed assets, Canva for faster turnaround, and HubSpot for email, are a reasonable set. The question is whether they are being used in a coordinated way or in parallel, each producing slightly different-looking output depending on who needs something quickly.

The AI drafting question

You are already using ChatGPT to draft marketing copy, and you have a sensible quality-review step in place before anything is published. That is a reasonable starting position for a business operating under MHRA advertising rules.

The important practical step to add now, before it becomes mandatory rather than best practice, is a simple record of which content was AI-drafted and which was written from scratch. The EU AI Act's transparency duty under Article 50 requires that AI-generated content be clearly disclosed, with that requirement applying from August 2026.

If any of your content reaches customers in the EU, that applies to you directly; if you are UK-only today, the direction of expectation is clear and preparing now costs very little. A log does not need to be complicated: a column in your content calendar noting the origin of each piece is enough to make disclosure a straightforward process rather than a retrospective problem.

On the wider question of using AI for tender responses and for summarising clinical evidence, which you mentioned exploring: that is a different level of risk than drafting a product description, and the board is right to want a policy in place before it goes further. That governance work is outside the scope of this roadmap and is covered by Anicca's separate AI Adoption Roadmap.

The practical steps that will compound

• The single highest-return action here is writing a one-document brand and content guide: not a 40-page brand bible, but a clear, usable reference covering your approved claims, the language you use to describe your products, your tone in clinical versus commercial contexts, and the visual rules that sit alongside the logo. Everything else you do in content becomes easier and faster once this exists.

• Build a simple content calendar that maps your existing content types against the topics you want to own in your market. The clinical bulletin, the CPD webinars, the evidence sheets and the catalogue should all be pulling in the same thematic direction, planned together rather than produced in separate cycles. A two-person team cannot increase volume significantly, but you can increase coherence without adding effort, and coherence is what builds search visibility and buyer trust over time.

• The evidence sheets you produce at every product launch are an underused asset. Structured correctly and published digitally, they become the foundation of organic search content that keeps working long after the launch window closes. Anicca's SEO work in this context is specifically about helping you build that pipeline so the content you are already creating does more than one job.

• Your HubSpot account is the right tool to make this systematic: sequences tied to product launches, nurture flows built from your webinar and bulletin content, and a clear map of which content reaches which contact type at which stage. At the moment it sounds as though HubSpot is used primarily for sending rather than for building a structured content journey, and closing that gap does not require more content, just better organisation of what you already have.

The problem is that the digital channels supporting those relationships have no performance framework behind them, so you cannot tell which ones are earning their keep and which are coasting.

Paid search

• You are spending £2,000 a month on Google Ads and generating roughly 35 sample requests a month. That puts your cost per sample request at around £57, which looks reasonable in isolation, but without knowing how many of those sample requests convert into practice accounts, you cannot connect that spend to your stated cost of winning a customer (roughly £600 per new practice). The conversion chain is incomplete, and incomplete chains mean you are flying partly blind.
• There are no formal digital targets holding this channel to account. No target cost per sample request, no minimum conversion rate from request to account, no view of whether the £2,000 monthly spend is the right number or an accident of history. The risk is not that the channel is failing, it is that you would not know if it were.
• Connecting Google Ads performance to actual account wins, rather than stopping at sample requests, is the practical fix. Armadello would bring that connection into one view, mapping spend through to enquiry, through to conversion, so the question "is paid search pulling its weight?" has an answer grounded in business outcomes rather than platform-reported figures.

Organic and referral traffic

• Organic search accounts for 38% of your sessions over the last 12 months, your single largest traffic source. Given your resource constraints, that proportion is doing real work. The question is whether the content earning that traffic is the right content, covering the clinical and product questions your target buyers are actually searching for, or whether it is drawing in traffic that never had any intention of becoming a customer.
• Your overall enquiry rate from the website sits at 0.7% of sessions. Across 58,000 sessions in a year, that produces roughly 420 enquiries. Whether that is good or poor depends on how many of those enquiries are genuinely qualified, which your current setup cannot easily answer.
• Referral traffic at 15% is worth watching carefully. In a regulated sector where trust travels through professional networks, referral links from clinical bodies, journal publishers, NHS supplier directories, or training providers carry both ranking value and credibility that a paid ad cannot replicate. That channel rarely gets deliberate investment, but it tends to reward it.

AI search and clinical evidence visibility

• You have already identified the right problem here. Clinicians are using AI tools to compare dressings and the answers cite whichever clinical evidence is most visible online, which right now may be your competitors' studies rather than yours. This is not a future concern, it is already shaping how your products are evaluated before a buyer ever visits your website or takes a sales call.
• The practical response is to make your clinical evidence machine-readable and well-structured: published studies linked clearly from your product pages, claims matched to their source documents, and evidence summaries written in plain language that AI tools can parse and attribute. This is also precisely where your regulatory caution is an asset rather than a constraint. Evidence that is accurately presented and clearly sourced is far more likely to be cited than competitor content that makes loose claims. Anicca's SEO and content work covers how to structure this, within MHRA-compliant bounds.

Social and email

• LinkedIn and YouTube are your active channels, both running on organic posting. That is a reasonable starting point for a business with no dedicated marketing headcount, but organic reach on LinkedIn in particular has compressed significantly over the last two years. Occasional paid promotion is not a substitute for a consistent plan. Even a modest, well-targeted LinkedIn campaign directed at procurement leads, practice managers, or clinical commissioners would give you data on what messaging converts, which you do not currently have.
• Email accounts for 10% of your sessions, a meaningful share given the size of your list is likely relatively small compared to a consumer brand. That proportion suggests your existing subscribers are engaged. The gap is whether email is being used as a nurture tool for practices already in conversation with sales, or primarily as a broadcast channel. In a sector where the sales cycle runs through relationship and tender, email that maps to where a prospect is in that process tends to outperform email that does not.

The underlying measurement gap

• None of your digital channels is currently held to a commercial target. That means when budget decisions are made, they default to familiarity or inertia rather than evidence. Field sales and telesales are your dominant acquisition channels and they are likely to remain so, but the digital channels exist to support them: warming prospects before a call, reinforcing a sales conversation with clinical content, and capturing the inbound enquiry from the clinician who found you through AI search or a referral link. Without measurement connecting digital activity to those outcomes, you cannot make the case for more investment or identify where the current spend is being wasted.
• The practical first step is agreeing on what a successful digital outcome actually looks like for your business, not a platform metric like impressions or clicks, but a business outcome: a sample request from a new practice, a qualified enquiry that your sales team can follow up, or a downloaded clinical study that signals genuine intent. Once those outcomes are defined, Armadello can track them across channels consistently, so every pound of digital spend is judged against the same standard.

The question is where the disconnection is costing you most.

• You describe your ecommerce platform as "other," which suggests it is either a bespoke build, a sector-specific clinical procurement system, or something outside the standard commercial platforms. Whatever it is, the first practical step is confirming whether it can be connected to your CRM and your analytics setup via an interface that lets systems exchange data automatically. If it cannot, every order, every customer record and every purchase history that lives in that system is invisible to everything else.

• The partial connection state you have described is often more problematic than being fully disconnected, because it creates a false sense of coverage. Some data flows automatically, some does not, and the business gradually stops questioning which is which. The result is that decisions get made on incomplete information without anyone realising it.

• Your fulfilment reliability for NHS and clinical clients is a genuine strength, and that reputation is worth protecting carefully. The risk is not in delivery itself but in what happens to the data around it: order confirmation, client communication records, delivery status and invoice data all need to be consistent across whichever systems hold them. If your clinical ordering platform and your CRM are not synchronised, a client-facing team member may not know an order has already shipped, or a renewal may be missed because the record in one system does not reflect what happened in another.

• ChatGPT and Microsoft Copilot are already in use, but without a clear picture of which systems they can reach, any automation you build on top of them will be limited to whatever data you can copy and paste manually. That is a ceiling worth thinking about now, particularly as you explore using AI to support tender responses and clinical evidence summaries.

• The practical first move is a system map: a simple document listing every tool in use, what data each one holds, which pairs are currently connected and which are not, and where someone is currently re-keying or copying information by hand. That map usually reveals one or two connections that would remove a disproportionate amount of manual work if they were built. In a regulated environment, it also gives you the foundation you will need before any system is connected to an AI tool, since the board's instinct to have a proper policy in place before customer data touches an AI tool is exactly right.

• Armadello would be relevant here once the underlying connections improve. At present, if your clinical platform, your CRM and your Google Ads account are not feeding into one reporting view, you cannot see the full picture from enquiry through to order and margin without assembling it by hand. Armadello would bring those sources into one place so leadership has a single reliable view rather than reconciling separate exports.

That is not a minor inefficiency: it means leadership is routinely making decisions against figures that are already weeks old by the time they land.

• Your five weekly KPIs, revenue, orders, pipeline, retention and delivery against SLA, are the right things to track. The problem is not the choice of metrics but where they live. Right now no single view holds all five. Your commercial director owns sales reporting through Power BI, finance owns margin, and quality owns complaint and vigilance statistics. Each set is probably accurate within its own domain; the gap is between them.

• Power BI is a capable tool and you are already using it for sales reporting, so the platform is not the issue. The issue is that it is not yet connected to your marketing and website performance data. Organic search accounts for 38% of your sessions, paid search on Google Ads for 13%, and you are generating around 420 enquiries a year from 58,000 sessions. Leadership currently has no straightforward way to see how that digital activity connects to the pipeline figure they track every week.

• Your Google Ads spend of around £2,000 a month is producing roughly 35 enquiries a month by the data we have. That is a cost per enquiry worth knowing precisely, and at the moment nobody is looking at it alongside pipeline and closed revenue in the same place. Without that joined-up view, it is genuinely difficult to judge whether the spend is pulling its weight or needs adjusting.

• The monthly board pack being assembled by hand is the most avoidable friction here. A named person already owns data quality, which is further along than most businesses at this stage. The next step is removing the manual compilation work, not the ownership model. Armadello, Anicca's reporting product, is designed to do exactly this: it brings channel performance, spend, enquiries and commercial outcomes into one live view so that the board pack is no longer something that needs building each month, it is simply there.

• The practical gain from connecting these data sources is not just time saved on assembly. It is that problems become visible earlier. If enquiry volume drops in week two of a month, the right people see it in week two, not when the board pack lands. In a regulated environment where sales cycles are long and individual contracts carry significant value, spotting a pipeline slowdown four weeks late has a real commercial cost.

• One genuinely useful near-term step, separate from any new tooling, is agreeing a single source of truth for each of your five KPIs at the point of definition. Revenue as reported by finance and revenue as reported by the commercial director can differ by timing, currency of data or how part-completed orders are treated. Resolving those definitions before connecting systems will make the connected view trustworthy rather than just faster.

What your margins actually tell you

• You have three meaningfully different gross margin bands sitting across your product mix: advanced dressings at 45-55%, diagnostic consumables at 30-40%, and clinical skincare at around 60%. A typical practice account runs at roughly 46% gross margin and is worth about £7,900 a year. Those are genuinely useful numbers, but only if you know which channel, which campaign, or which type of account is actually delivering them rather than diluting them.

• Your revenue is weighted 70% towards consumables reorders and 15% towards framework agreement volumes. Both are relatively predictable and high-retention income streams, which is commercially healthy. The question worth asking is whether your marketing spend, currently between £3,000 and £6,000 a month and focused almost entirely on trade literature, exhibitions and a modest website budget, is being tested against any of those margin figures. If it is not, you are making budget decisions on spend and activity rather than return.

• Your Google Ads account is spending around £2,000 a month and generating approximately 35 enquiries a month, which works out at roughly £57 per enquiry. Whether that is good or poor value depends entirely on which product lines those enquiries convert into, at what margin, and what the lifetime value of the resulting account looks like. At the moment, you do not appear to have a clean way to connect those dots end to end.

• The Excel and Power BI combination you use to track costs and margins can absolutely support good commercial analysis, but the honest question is whether it does in practice. Pulling channel spend, cost of goods, fulfilment cost, and account-level margin into a single, timely view in Excel is genuinely difficult to do consistently, and Power BI only reflects what has been fed into it accurately and recently. If the margin picture you are working from is already a few weeks old by the time anyone looks at it, that is a meaningful lag for a business where reorder patterns and logistics costs can shift.

• Your software spend runs at approximately £4,800 a month across all categories. That is a reasonable amount for a business at this size, but it is worth asking whether each subscription is being actively used and whether any of the tools overlap in what they do. The fact that your current reporting sits primarily in Excel suggests that at least some of your software investment may not be doing the analytical heavy lifting you might expect it to.

What a cleaner commercial view would give you

• The practical improvement here is not replacing your existing tools but connecting the numbers they hold. You need to know what it costs to win each type of account, what each channel actually returns after media spend and staff time are counted, and whether your marketing budget is weighted towards the channels delivering your better-margin accounts or simply the most visible ones.

• Armadello would bring your channel spend, traffic, enquiry volume and account-level data into one reporting view, so that a question like "what did last month's Google Ads spend return against our diagnostic consumable margin" has an answer you can act on rather than one you have to assemble manually from multiple exports.

• With your return rate under 1% and logistics as a named top-three cost, there is an opportunity to make fulfilment cost per order type a regular part of your margin reporting rather than an occasional sense-check. Bulk orders for framework accounts and individual starter bundle shipments are likely to carry very different fulfilment costs per pound of revenue, and that difference matters when you are deciding where to focus account development effort.

• Where your AI adoption work moves forward, particularly the exploration of AI for tender responses and clinical evidence summarisation, those activities will have their own cost and time implications. The commercial model around AI tools belongs in your AI Adoption Roadmap rather than here, but flagging it now is useful: any AI tooling that feeds into sales or marketing processes will eventually need to sit inside your margin and cost-of-sale thinking, not outside it.

The gap is not that you are ignoring compliance; it is that marketing activity, website tracking, and AI tool use are growing faster than the documented controls around them.

Data and consent

• Your DPA coverage across HubSpot, the ordering portal host, couriers, and your outsourced payroll provider is a strong foundation, and annual review as part of ISO surveillance is the right discipline. The question is whether every marketing and analytics tool added to your website or campaigns since the last review is on that list. Tracking tools, advertising pixels, and form handlers accumulate quietly, and each one is a potential gap between what your cookie notice says and what is actually running.

• Data protection law (GDPR) requires that your cookie consent mechanism accurately reflects every tool collecting data on your site. If you have added or changed tools in Google Ads or on your website since your last consent review, a light-touch audit across your live cookie setup, your consent banner, and your current DPA list would tell you quickly whether everything is aligned. This is not a large exercise, but it needs one named owner and a clear date to complete it.

• Because you operate in both UK and EU markets, you are subject to both the UK GDPR and the EU GDPR in parallel. They are closely aligned but not identical, and NHS framework contracts add a further layer of data-handling obligations that sit alongside the standard commercial requirements. Your annual ISO review is the natural moment to confirm that your EU-facing data flows are documented separately from your UK ones, rather than treated as a single regime.

Medical device and advertising regulation

• The UK's post-Brexit medical device regulatory framework and the EU Medical Device Regulation transition are the areas you flagged as live concerns, and rightly so. Without citing specific deadlines that have not been confirmed to us, the practical implication for marketing is this: any product claims, clinical references, or promotional materials you produce need to be checked against the current status of each product's regulatory classification before they are published. This is especially important where your content team or your marketing manager is producing materials at pace.

• The Advertising Standards Authority's rules on health product claims are enforced independently of MHRA classification, so a claim that is accurate in a clinical sense can still breach ASA guidance if it implies efficacy or safety in a way that has not been substantiated in the ad itself. Your review process for marketing materials needs to include an explicit sign-off step that covers both clinical accuracy and advertising compliance, not just one or the other.

AI-generated content and disclosure

• You are already doing the right thing by passing AI-drafted content through a quality review before it is published, and by keeping AI use away from customer data while your policy is still in draft. The EU AI Act's transparency duty under Article 50 requires clear disclosure when a customer is interacting with AI-generated content or an AI system, and this applies from August 2026 for EU-facing businesses. Given that you sell into EU markets, this is a real obligation rather than a distant signal. Folding an AI-content disclosure standard into your existing review process, alongside the consent and DPA audit described above, is more efficient than treating it as a separate exercise later.

• Your staff are using ChatGPT and Microsoft Copilot in day-to-day work, and your board wants a proper policy in place before any of that use touches customer data. That is exactly the right instinct, and the board is correct to treat it as urgent. Defining what is and is not permitted, which tools are sanctioned, and where human review is mandatory is work that goes well beyond marketing-data compliance and into how your organisation governs AI use across every function. That is the territory of Anicca's separate AI Adoption Roadmap, not this report. We would recommend treating that as a parallel workstream rather than waiting for it to resolve before progressing marketing compliance.

The practical first move

• Nominate one person to own the compliance audit for marketing and website data. That person's first task is to list every tool currently active on your website and in your marketing operations, check each one against your current DPA schedule, and confirm that your cookie consent notice accurately describes what is running. Where gaps appear, they are fixed in that same pass. AI-content disclosure standards and your existing review process for medical claims should be reviewed at the same time, since the same materials are subject to all three.

• Armadello would give you a single view of which channels and tools are active across your marketing, which makes the consent and DPA audit considerably easier to scope and maintain. If you are currently checking this by going into individual platform accounts, that process is both slower and more likely to miss something added by a third party or an agency.